CompletedNCT02009163
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating disorders
Researchers compared Lisdexamfetamine dimesylate and placebo to find out how the approaches affected how long people remain free of a new mood episode in adults with binge eating.
Medication studyAges 18–55Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Lisdexamfetamine dimesylate and placebo to find out how the approaches affected how long people remain free of a new mood episode in adults with binge eating.
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Fort Myers and 52 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: January 27, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 418
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Germany, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02009163
- Official title
Show the full official title
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Get this study by email
Recruitment & locations
CompletedFort Myers, United States · Lauderhill, United States · Leesburg, United States
46 more locations
- Maitland, United States
- North Miami, United States
- Orlando, United States
- South Miami, United States
- Atlanta, United States
- Libertyville, United States
- Indianapolis, United States
- Prairie Village, United States
- Wichita, United States
- New Orleans, United States
- Belmont, United States
- Boston, United States
- Watertown, United States
- Rochester Hills, United States
- Albuquerque, United States
- Brooklyn, United States
- Raleigh, United States
- Cincinnati, United States
- Dayton, United States
- Mason, United States
- Portland, United States
- Salem, United States
- Allentown, United States
- Warwick, United States
- Anderson, United States
- Greer, United States
- Mt. Pleasant, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Plano, United States
- San Antonio, United States
- Bellevue, United States
- Seattle, United States
- Mississauga, Canada
- Pointe-Claire, Canada
- Berlin, Germany
- Dresden, Germany
- Hanover, Germany
- Schwerin, Germany
- Westerstede, Germany
- Barcelona, Spain
- Madrid, Spain
- Malmö, Sweden
- Stockholm, Sweden
Questions about this study
What did researchers investigate?
Researchers compared Lisdexamfetamine dimesylate and placebo to find out how the approaches affected how long people remain free of a new mood episode in adults with binge eating.
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine dimesylate.
Who was this study for?
Listed age limits: 18 years to 55 years.
